198 related articles for article (PubMed ID: 29145283)
1. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).
Niu H; Yang J; Yang K; Huang Y
Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283
[TBL] [Abstract][Full Text] [Related]
2. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
[TBL] [Abstract][Full Text] [Related]
3. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A
Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521
[TBL] [Abstract][Full Text] [Related]
5. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
Wei H; Fang N; Guo L; Wu Z; Zhou Q
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
[TBL] [Abstract][Full Text] [Related]
6. Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.
Huang YQ; Guan H; Liu CH; Liu DC; Xu B; Jiang L; Lin ZX; Chen M
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173228
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
Wang HL; Liu P; Zhou PY; Zhang Y
Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.
Santoro A; Pannone G; Carosi MA; Francesconi A; Pescarmona E; Russo GM; Feola A; Losito S; Franco R; Nappi L; Aquino G; De Rosa G; Di Domenico M; Bufo P
J Cell Biochem; 2013 May; 114(5):1174-82. PubMed ID: 23192464
[TBL] [Abstract][Full Text] [Related]
10. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis.
Shi DT; Han M; Gao N; Tian W; Chen W
Tumour Biol; 2014 Feb; 35(2):943-8. PubMed ID: 23982879
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
12. Association Between
Markulin D; Vojta A; Samaržija I; Gamulin M; Bečeheli I; Jukić I; Maglov Č; Zoldoš V; Fučić A
Cancer Genomics Proteomics; 2017; 14(5):363-372. PubMed ID: 28871003
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
14. Association between Ras association domain family 1A promoter methylation and esophageal squamous cell carcinoma: a meta-analysis.
Yang JZ; Ji AF; Wang JS; Chen ZY; Wen SW
Asian Pac J Cancer Prev; 2014; 15(9):3921-5. PubMed ID: 24935575
[TBL] [Abstract][Full Text] [Related]
15. RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.
Shou F; Xu F; Li G; Zhao Z; Mao Y; Yang F; Wang H; Guo H
Onco Targets Ther; 2017; 10():247-257. PubMed ID: 28123306
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
[TBL] [Abstract][Full Text] [Related]
17. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis.
Huang YZ; Wu W; Wu K; Xu XN; Tang WR
Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469
[TBL] [Abstract][Full Text] [Related]
18. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
[TBL] [Abstract][Full Text] [Related]
19. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
20. The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.
Ge YZ; Xu LW; Jia RP; Xu Z; Feng YM; Wu R; Yu P; Zhao Y; Gui ZL; Tan SJ; Song Q
Tumour Biol; 2014 Apr; 35(4):3881-90. PubMed ID: 24353088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
